祥生医疗(688358) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2025 was ¥107,011,721.01, a decrease of 6.68% compared to the same period last year[3] - Total profit for Q3 2025 reached ¥25,751,034.69, an increase of 63.21% year-on-year, primarily due to changes in exchange gains and losses[9] - Net profit attributable to shareholders for Q3 2025 was ¥24,224,141.58, reflecting a year-on-year increase of 41.95%[10] - Basic earnings per share for Q3 2025 was ¥0.22, up 46.67% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2025 was CNY 343,166,004.60, a decrease of 5.5% compared to CNY 362,245,220.14 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 93,920,462.46, a decline of 4.9% from CNY 98,408,552.70 in 2024[20] - Earnings per share for the first three quarters of 2025 were CNY 0.84, compared to CNY 0.88 in the same period of 2024[21] Cash Flow - Net cash flow from operating activities for Q3 2025 was ¥19,586,474.53, an increase of 19.70% compared to the same period last year[3] - Cash inflow from operating activities for the first three quarters of 2025 was CNY 374,078,230.83, slightly down from CNY 378,670,229.13 in 2024[24] - The net cash flow from operating activities was $73,290,282.91, an increase from $70,624,175.74 in the previous period[25] - The cash flow from operating activities decreased slightly to $300,787,947.92 from $308,046,053.39[25] - The company reported a net decrease in cash and cash equivalents of $19,973,458.26, contrasting with an increase of $526,483,394.87 in the previous period[27] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥1,577,347,808.07, a decrease of 1.23% from the end of the previous year[5] - Total liabilities as of the end of the reporting period were CNY 177,240,527.05, a slight increase from CNY 176,423,213.57 in the previous year[17] - The company’s total assets amounted to CNY 1,577,347,808.07, a decrease from CNY 1,597,009,767.62 in the previous year[17] - The total current assets are reported at ¥1,384,870,679.88, slightly down from ¥1,405,034,429.79 in the previous period[15] - The total non-current assets are reported at ¥192,477,128.19, slightly up from ¥191,975,337.83[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,167[11] - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 45,360,000 shares, representing 40.46% of total shares[11] - There are no significant changes in the top 10 shareholders or their shareholding status during the reporting period[12] Research and Development - Research and development expenses totaled ¥18,956,993.78 for Q3 2025, a decrease of 16.45% year-on-year, representing 17.71% of total revenue[5] - Research and development expenses for the first three quarters of 2025 were CNY 56,570,044.39, a decrease of 8.4% from CNY 61,760,390.24 in 2024[19] - The company plans to continue focusing on R&D and market expansion strategies to enhance future growth prospects[4] Other Financial Metrics - Non-recurring gains and losses for Q3 2025 amounted to ¥1,083,497.03, with significant contributions from government subsidies and asset disposals[7] - The company reported a decrease in other comprehensive income, with a net amount of CNY -2,573,798.70 compared to CNY 1,703,584.49 in the previous year[17] - The company's cash and cash equivalents as of September 30, 2025, amount to ¥897,646,076.93, a decrease from ¥985,616,661.93 as of December 31, 2024[14] - The company's inventory stands at ¥116,342,235.02, down from ¥126,328,601.45[15] - Fixed assets are valued at ¥68,416,916.13, a decrease from ¥76,314,597.43[15]